866-997-4948(US-Canada Toll Free)

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 36 Pages

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 1 respectively.Heterozygous familial hypercholesterolemia (heFH).

Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heterozygous familial hypercholesterolemia (heFH) Overview 6
Therapeutics Development 7
Pipeline Products for Heterozygous familial hypercholesterolemia (heFH) - Overview 7
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics under Development by Companies 8
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Heterozygous familial hypercholesterolemia (heFH) - Products under Development by Companies 12
Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development 13
Gemphire Therapeutics Inc 13
Merck & Co Inc 14
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Combination Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 23
(atorvastatin calcium + ezetimibe) - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
anacetrapib - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
gemcabene calcium - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
MGL-3196 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
MGL-3745 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects 31
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products 32
Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones 33
Featured News & Press Releases 33
Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia 33
Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects 33
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Gemphire Therapeutics Inc, H2 2016 13
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Merck & Co Inc, H2 2016 14
Assessment by Monotherapy Products, H2 2016 15
Assessment by Combination Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 22
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H2 2016 31
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, H2 2016 32

List of Figures
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Targets, H2 2016 17
Number of Products by Stage and Targets, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Stage and Molecule Types, H2 2016 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *